>2 cm, recurrence, depth >4-5 mm, poor differentiation, perineural invasion, history of CLL/SLL/organ transplantation) but no nodal metastases. All patients underwent excision of the primary tumor with SLNB. Specimens were analyzed for evidence of regional metastases.
Head and Neck Surgery
Signaling Networks in Methylated HPV Genomes Maria J. Worsham, PhD (presenter) ; Kang Mei Chen, MD; Tamer A. Ghanem, MD, PhD; George Divine, PhD Objective: HPV-positive (+) and HPV-negative (-) HNSCC are biologically distinct with a prognostic advantage for HPV+ patients compared to HPV-cases. The goal of this study was to identify differentially methylated genes in HPV+ vs HPVprimary HNSCC genomes with clues to signaling networks that impact key biological functions.
Method: DNA from 4 HPV(+) and 4 HPV(-) freshly frozen primary HNSCC were subject to comprehensive genome-wide methylation profiling using the HumanMethylation27 Bead Array, which measures methylation as a β value ranging from 0 to 1. Genomatix Pathway System software was applied to build a network from differentially methylated genes.
Results: Two-fold methylation differences were observed between HPV+ and HPV-cases for 1168 genes. Pathway analysis applied to investigate the biological role of the 1168 differentially methylated genes revealed 8 signals transduction pathways forming a network of 66 genes, of which 62% are hypermethylated (41 of the 66). Of the 8 signal transduction pathways, the Beta catenin degradation, E-cadherin, ErbB receptor, and Integrin signaling networks have immediate association with HNSCC. The other 4 pathways are c-kit, ion channels, ppara elements, and RXR and RAR heterodimerization signaling events.
Conclusion: Signaling events in the cell play a critical role in the execution of key biological functions. Our results demonstrate that in signal transduction pathways, HPV genomes harbor a larger proportion of hypermethylated genes than HPV-negative tumors with potential for these genes as differential targets in HPV related HNSCC.
Skin and Mucosal Malignancy with Solid Organ Transplantation Owen A. F. Darr (presenter); Waleed M. Abuzeid, MD; Emily Light; Michael J. Englesbe, MD; Jeffrey S. Moyer, MD Objective: 1) Measure the prevalence of cutaneous malignancies as well as mucosal head and neck squamous cell carcinoma (HNSCC) using a large database of solid organ transplant recipients. 2) Assess the risk of malignancies among each organ type and age at transplant.
Method:
Using the University of Michigan transplant database, electronic records from 3496 patients transplanted from 1996-2006 were queried using EMERSE (Electronic Medical Record Search Engine), with search terms screening for target malignancies. Once cases were identified, differences in prevalence based on independent variables were examined using a generalized linear model.
Results:
Of patients queried, 13% (n = 440) developed a cutaneous malignancy (66% involving the head and neck) and 0.6% (n = 19) developed mucosal HNSCC. Of the cutaneous malignancies, 7.3% were a squamous cell carcinoma, and 7.1% were a basal cell carcinoma. Lung transplants were associated with a higher risk of cutaneous malignancy (P = .0006) with the predominant histology favoring the development of SCC (P = .05). Age was associated with skin cancer of the head and neck (P = .0001), with increased risk among patients transplanted in the third, fourth, or fifth decade. In this cohort, mucosal HNSCC was not associated with one transplant site over another.
Conclusion: Transplant recipients carry an elevated risk of acquiring cutaneous and mucosal malignancies, with most lesions affecting the head and neck. The risk of SCC is similar to BCC. Patients transplanted before the age of 50 have an increased risk of malignancy of the head and neck, and those receiving lung transplants have the highest incidence of skin cancer.
Head and Neck Surgery sleX Relationship with Head and Neck Cancer Stem Cells CSC Silvana Papagerakis, MD, PhD (presenter)
Objective: Disseminated head and neck cancer is still considered incurable, as therapeutic options for advanced metastatic head and neck squamous cell carcinomas (HNSCC) are limited. It is not known if CSCs are the metastatic population, nor how they carry out the metastatic process. Our previous studies indicated that metastatic HNSCC express high levels of an
